VEGFA and glioblastoma: Circulating levels of the chemokine SDF1α rise in patients who evade various anti-VEGF therapies including rectal carcinoma with bevacizumab, glioblastoma multiforme with cediraninb, hepatocellular carcinoma with sunitinib, and soft tissue sarcoma with sorafenib [82].